Trinity Biotech
Business Services · Ireland · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Ida Business Park, Bray, Leinster, A98 H...Phone Number
+353 8003253424Website
www.trinitybiotech.comRevenue
$61.6 MillionStock Symbol
TRIBIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
1
About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide.Explore more
Trinity Biotech Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Trinity Biotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Trinity Biotech, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Trinity Biotech had a recent Job posting/layoffs
Product Launch: Get notified when Trinity Biotech launches new products
Earning: See what the market has to say on Trinity Biotech recently announced quarterly report
Funding: Get notified immidiatlly once Trinity Biotech has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Trinity Biotech
Check if Trinity Biotech has recently received funding, and reach out quickly before it becomes old news!
Check out if Trinity Biotech is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Trinity Biotech as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Trinity Biotech is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Trinity Biotech is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Trinity Biotech.
Trinity Biotech financials insights
Gather financial insights about Trinity Biotech, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Debt
$115M
2022
Corporate Investment
$45M
2023
Debt
$5M
2024
Other Financing Round
$5.5M
2025
Debt
$4M
Debt
$5M
2026
Unspecified
$25M
Trinity Biotech Tech Stack
A closer look at the technologies used by Trinity Biotech
Most Recent Scoops
Person-Based
Partnership, Product Development, Bioengineering
Person-Based
Medical Research, Healthcare Technology
Person-Based
Data Center, Infrastructure
Person-Based
Earnings, Pharmaceuticals, Finance
Person-Based
Earnings, Pharmaceuticals, Finance
Trinity Biotech News & Media
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
DUBLIN, July 22, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), (the “Company”) today announced that it plans to change the ratio of the American depositary shares (“ADSs”) representing its Class A ordinary shares from one (1) ADS representing twenty (20) Class A ordinary shares to one (1) ADS representing six hundred (600) Class A ordinary shares.New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring
- Analysis of over 5,000 hours of clinical wear data validates Trinity Biotech’s CGM+ 's purpose-built capability to distinguish nocturnal compression-related false lows from true blood glucose lowsTrinity Biotech’s Trinovium Secures Open Compute Project Membership, Advancing Hyperscale Market Access and Commercial Validation for AI Data Center Liquid Cooling
- Milestone an important step in launching Trinovium within the global AI data center ecosystemTrinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville
DUBLIN, June 29, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, today announced that it has formally provided notice of termination to YA II PN, LTD., an affiliate of financing partner Yorkville Advisors Global, in respect of its Standby Equity Purchase Agreement (the “SEPA”) for an equity line of credit facility.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Trinity Biotech
Sign Up For FreeTo access detailed company insights
Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic... Read More
